2. Apoptosis Metabolic Enzyme/Protease Cell Cycle/DNA Damage PI3K/Akt/mTOR Protein Tyrosine Kinase/RTK
  3. Apoptosis MMP MARK PI3K Akt ROS Kinase DNA/RNA Synthesis
  4. Kukoamine B mesylate

Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .

For research use only. We do not sell to patients.

Kukoamine B mesylate Chemical Structure

Kukoamine B mesylate Chemical Structure

CAS No. : 1375179-86-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Kukoamine B mesylate:

Kukoamine B mesylate Related Antibodies

Top Publications Citing Use of Products

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. [1][2][3][4].

In Vitro

Kukoamine B (5-20 μM, 2 h) increases cell viability, and prevents plasma membrane from damaging in SH-SY5Y cells[2].
Kukoamine B (5-20 μM, 2 h) attenuates H2O2-induced Apoptosis and mitochondria membrane potential (MMP) loss in SH-SY5Y cells[2].
Kukoamine B (5-20 μM, 2 h) demonstrates anti-oxidative stress effects by modulating the MAPKs and PI3K-AKT signaling pathways in SH-SY5Y cells[2].
Kukoamine B (10-20 μM, 3 days) increases osteoblast differentiation and the mineralized nodule formation of preosteoblastic MC3T3-E1 cells[3].
Kukoamine B (50-200 μM, 12 h) is a dual inhibitor of LPS- and CpG DNA-induced TNF-a and IL-6 release from RAW 264.7 cells and murine peritoneal macrophages[4].
Kukoamine B (50-200 μM, 12 h) down-regulates two receptors (TLR4 and TLR9) and two important enzymes (iNOS and COX-2) mRNA expressions upregulated by LPS and CpG DNA in RAW 264.7cells[4].
Kukoamine B (0-200 μM, 30min-2 h) inhibits IkB-a and p38 phosphorylation and NF-kB activation induced by LPS and CpG DNA in RAW 264.7cells [4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Kukoamine B mesylate Related Antibodies

Cell Viability Assay[2]

Cell Line: SH-SY5Y cells
Concentration: 5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
Incubation Time: 2 h
Result: Prevented cell death and improved cell viability dose-dependently.
Lowered the LDH release.
Increased the activity of CAT, SOD, and GSH-Px, and reduced the MDA production

Apoptosis Analysis[2]

Cell Line: SH-SY5Y cells
Concentration: 5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
Incubation Time: 2 h
Result: Decreased total apoptotic cells and late apoptotic cells.

Immunofluorescence[2]

Cell Line: SH-SY5Y cells
Concentration: 5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
Incubation Time: 2 h
Result: Increased the fluorescence intensity of Rho (Rhodamine) 123.
Decreased the ROS production.

Western Blot Analysis[2]

Cell Line: SH-SY5Y cells
Concentration: 5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
Incubation Time: 2 h
Result: Restored the mitochondria function via inhibiting the ratio of Bcl-2/Bax.
Decreased cytochromec, caspase-3, caspase-9, p-p38, p-ERK and p-JNK expression.
Increased p-AKT expression.

RT-PCR[4]

Cell Line: RAW 264.7 cells
Concentration: 0, 100, 200 μM
Incubation Time: 12 h
Result: Down-regulated the mRNA expression of two receptors (TLR4 and TLR9) and two important enzymes (iNOS and COX-2).

Western Blot Analysis[4]

Cell Line: RAW 264.7 cells
Concentration: 0, 100, 200 μM
Incubation Time: 30 min-2 h
Result: Suppressed the IkB-a and p38 phosphorylation as well as the degradation of IkB-a.
In Vivo

Kukoamine B (20, 50 mg/kg, i.g., daily, 9 weeks) reduces inflammation and blood glucose without body weight gain or liver mass increase[1].
Kukoamine B (2, 5 mg/kg, p.o., daily, 12 weeks) demonstrates the anti-osteoporotic effects in ovariectomized (OVX) mice[3].
Kukoamine B (1.25-60 mg/kg, i.v., only one injection or very 8 h for 3 days) protects mice challenged with E. coli and reduces the circulatory levels of LPS and TNF-a in sepsis model mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male, 4-week old db/db mice (BKS.Cgm+/+Leprdb/J) and wildtype (WT) mice (C57BLKS/J-m+/+ db). A spontaneous type 2 diabetic animal model[1].
Dosage: 20, 50 mg/kg
Administration: i.g., daily, 9 weeks
Result: Successfully controlled the augment of blood glucose with age increase.
Reduced levels of 29 inflammatory markers such as IL-2, IL-3, IL-4, IL-5, IL-6, IL-7 and IL8.
Animal Model: Seven-week-old female ddy mice underwent either an ovariectomy or sham-operated surgery[3].
Dosage: 2, 5 mg/kg
Administration: p.o., daily, 12 weeks
Result: Inhibited the OVX-induced BMD loss in the right femur bone and restored the impaired bone structural properties of BV/TV, Tb.Th, Tb.N, and Tb.Sp.
Animal Model: Kunming (KM) mice, 4–6 weeks old, 18–20 g, male and female in equal number. Mice were injected with heat-killed E. coli (EC, 1.0 * 1011 CFU•kg-1) in order to establish the sepsis model.[4].
Dosage: 1.25, 2.5, 5, 10, 15, 30, 60 mg/kg
Administration: 80 mice (15, 30, 60 mg/kg), i.v., only one injection; 100 mice (1.25, 2.5, 5 mg/kg), i.v., every 8 h for 3 days; 96 mice, (60 mg/kg), i.v., once at 0, 2, 4, 6, 8 h after injection of EC.
Result: Significantly decreased the mortality rate from 87.5% to 62.5%, 62.5%, or 37.5% (15, 30, 60 mg/kg).
Decreased the mortality rate from 95% to 65%, 60% and 45% (1.25, 2.5 and 5 mg/kg).
Decreased the circulatory LPS and TNF-a levels in a time-dependent manner.
Molecular Weight

626.76

Formula

C29H46N4O9S
CAS No.
SMILES

O=C(CCC1=CC=C(C(O)=C1)O)NCCCNCCCCN(CCCN)C(CCC2=CC=C(C(O)=C2)O)=O.O=S(O)(C)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Kukoamine B mesylate Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kukoamine B1375179-86-4ApoptosisMMPMARKPI3KAktROS KinaseDNA/RNA SynthesisMatrix metalloproteinasesMicrotubule affinity regulating kinasePhosphoinositide 3-kinasePKBProtein kinase Binflammationanti-diabeticneuroprotectionoxidative stressosteoporosisovariectomized micesepsisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Kukoamine B mesylate
Cat. No.:
HY-N2393A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.